Meridian Bioscience (VIVO) Reports In-Line Q4 EPS

Meridian Bioscience (Nasdaq: VIVO) reported Q4 EPS of $0.19, in-line with the analyst estimate of $0.19. Revenue for the quarter came in at $48 million versus the consensus estimate of $46.2 million.

Meridian Bioscience reaffirmed FY2015 guidance.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Piper Sandler Reiterates Overweight Rating on KKR (KKR), 'highest conviction name'
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c